Back to News
Market Impact: 0.4
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
Source: Nasdaq
Healthcare & Biotech
Genmab reported positive Part C results from the Phase 1/2 RAINFOL-01 trial of investigational antibody-drug conjugate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The positive clinical update supports further development of Rina-S in a high-unmet-need oncology indication, though the article provided no efficacy or safety figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
GMAB0.75
More News
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- A 'weird' IPO pull, a tainted reputation and the stalled breakout moment for AI wearables
- Sports betting is increasingly the norm for Gen Z. Here’s why some financial and mental health experts are worried
- Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial
- US coastguard suspends search for six on board crashed medical jet
- CSL strikes US$1.6 billion licensing deal for rare disease drug